Mikael Pittet's Lab
My laboratory performs a research program on the host immune response in vivo with the main goal to offer valuable new ways to combat cancer. We use various modalities, including in vivo imaging, to study where, when and how immune cells are produced, traffic, and mediate regulatory or effector functions. The studies make use of both genetic mouse models, which allow manipulations and analyses of mechanisms and causality, and human patient material, to ensure that the results are anchored in clinical correlates. This dual approach gives opportunities for discovery of novel contributions of the immune response to tumor progression, new biomarkers useful for diagnosis and prognosis, and novel targets for therapeutic intervention. Dr. Pittet directs Cancer Immunology Program at CSB and collaborates with several immunology programs at Harvard Medical School, Massachusetts General Hospital and Massachusetts Institute of Technology.
In vivo imaging of immune cells at different scales.
Imaging modalities include single photon emission computed
tomography - X-ray computed tomography (SPECT-CT), fluorescence
mediated tomography (FMT), microscopic fiber optics, and intravital
multiphoton microscopy (IVM).
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Sci Transl Med. 2017;9(392):eaal0225 - PMID: 28566423
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Tumor Microenvironment: No Effector T Cells without Dendritic Cells.
Cancer Cell. 2017;31(5):614-615 - PMID: 28486102
PF4 Promotes Platelet Production and Lung Cancer Growth.
2017-05-12: Best of 2016
: An article by Pfirschke and Engblom from the Pittet laboratory
on how to improve cancer immunotherapy
is listed in the 2016 edition of “Best of Immunity” as one of the ten most-accessed articles from the Journal. Immunity publishes papers that report the most important advances in immunology research.
2017-05-11: Checking out checkpoints
: Immune checkpoint blockers (ICBs) are designed to activate the immune system against cancer. These drugs can be extraordinarily effective in some patients but not in others. Now, Mikael Pittet and colleagues have used molecular imaging to track ICBs in real time within tumors. Their study, published in Science Translational Medicine
, uncovers a mechanism of treatment resistance, which can be overcome with additional chemical modifications. See also: the Journal Cover
illustrating the “Tug-of-war with anti-PD-1” and interview with the authors
2017-04-27: The MGH Graduate Student Division
is pleased to announce that Mikael Pittet, PhD
is the winner of the 2017 MGH GSD Principal Investigator (PI) Mentoring Award. This award is given to an MGH PI who has contributed to the success of PhD graduate student(s) at MGH and demonstrated excellence in a number of ways.